Interim comes of a Phase 2 multice...
Interim comes of a Phase 2 multicenter subject of attention of clofarabine (Bioenvision, Inc., recent York, NY) show an overall rejoinder rate of 28% in heavily pretreated children with acute leukemia. The 39 make subordinates enrolled in the thought were refractory to all alternative therapy and had previously failed a median of three chemotherapy regimens. Fourteen subdues had acute myelogenous leukemia (AML) and
|